The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Empirical versus Preemptive Antifungal Therapy for High‐Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial
Abstract
BACKGROUND: Empirical antifungal therapy is the standard of care for neutropenic patients with hematological malignancies who remain febrile despite broad-spectrum antibacterial treatment. Recent diagnostic improvements may ensure the early diagnosis of potentially invasive fungal disease. Reserving antifungals for this stage may achieve similar survival rates and reduce treatment toxicity and costs. METHODS: In this multicenter, open-label, randomized noninferiority trial, we compared an empirical antifungal strategy with a preemptive one. Empirical treatment was defined as antibacterial treatment of patients who have persistent or recurrent fever. Preemptive treatment was defined as treatment of patients who have clinical, imaging, or galactomannan-antigen-assay evidence suggesting fungal disease. First-line antifungal treatment was amphotericin B deoxycholate (1 mg/kg/day) or liposomal amphotericin (3 mg/kg/day), depending on daily renal function. The primary efficacy outcome was the proportion of patients alive at 14 days after recovery from neutropenia. RESULTS: The median duration of neutropenia (neutrophil count, <500 cells/mm3) for the 293 patients enrolled was 18 days (range, 5-69 days). By intention-to-treat analysis, survival was 97.3% with empirical treatment and 95.1% with preemptive treatment. The lower 95% confidence limit for the difference in mortality was -5.9%, which was within the noninferiority margin of -8%. Probable or proven invasive fungal infections were more common among patients who received preemptive treatment than among patients who received empirical treatment (13 of 143 vs. 4 of 150; P < .05), and most infections occurred during induction therapy (12 of 73 patients in the preemptive treatment group vs. 3 of 78 patients in the empirical treatment group were infected during induction therapy; P < .01). Preemptive treatment did not decrease nephrotoxicity but decreased costs of antifungal therapy by 35%. CONCLUSIONS: Preemptive treatment increased the incidence of invasive fungal disease, without increasing mortality, and decreased the costs of antifungal drugs. Empirical treatment may provide better survival rates for patients receiving induction chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Walsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszynska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040446 · Cited by 919
Pizzo, P. A., Robichaud, K. J., Gill, F. A., & Witebsky, F. G. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90594-0 · Cited by 859
Odabasi, Z., Mattiuzzi, G., Estey, E., Kantarjian, H., Saeki, F., Ridge, R. J., Ketchum, P. A., Finkelman, M. A., Rex, J. H., & Ostrosky-Zeichner, L. (2004) · Clinical Infectious Diseases · doi:10.1086/421944 · Cited by 642
Maertens, J., Theunissen, K., Verhoef, G., Verschakelen, J., Lagrou, K., Verbeken, E., Wilmer, A., Verhaegen, J., Boogaerts, M., & Eldere, J. V. (2005) · Clinical Infectious Diseases · doi:10.1086/496927 · Cited by 592
Cited by
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Barlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., Srinivasan, A., Dellit, T. H., Falck-Ytter, Y. T., Fishman, N. O., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw118 · Cited by 3,061
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq147 · Cited by 704
Limper, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A., Davies, S. F., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2008-740st · Cited by 612
-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections: A Meta-analysis
Karageorgopoulos, D. E., Vouloumanou, E. K., Ntziora, F., Michalopoulos, A., Rafailidis, P. I., & Falagas, M. E. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq206 · Cited by 538
Maertens, J., Marchetti, O., Herbrecht, R., Cornely, O. A., Flückiger, U., Frêre, P., Gachot, B., Heinz, W. J., Lass-Flörl, C., Ribaud, P., et al. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.175 · Cited by 470
Self-citationGroll, A. H., Castagnola, E., Cesaro, S., Dalle, J.-H., Engelhard, D., Hope, W., Roilides, E., Styczynski, J., Warris, A., & Lehrnbecher, T. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70017-8 · Cited by 407
Cavassin, F. B., Baú-Carneiro, J. L., Vilas-Boas, R. R., & Queiroz-Telles, F. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00382-7 · Cited by 382
Prevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334
Lamoth, F., Cruciani, M., Mengoli, C., Castagnola, E., Lortholary, O., Richardson, M., Marchetti, O., & (ECIL-3), O. B. O. T. T. E. C. O. I. I. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir897 · Cited by 302
Marchetti, O., Lamoth, F., Mikulska, M., Viscoli, C., Verweij, P., Bretagne, S., & Groups, A. T. E. C. O. I. I. L. (. L. W. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.178 · Cited by 275
Self-citationAcute respiratory distress syndrome in patients with malignancies
Azoulay, E., Lemiale, V., Mokart, D., Pène, F., Kouatchet, A., Perez, P., Vincent, F., Mayaux, J., Benoit, D., Bruneel, F., et al. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3354-0 · Cited by 274
Mousset, S., Buchheidt, D., Heinz, W., Ruhnke, M., Cornely, O. A., Egerer, G., Krüger, W., Link, H., Neumann, S., Ostermann, H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-013-1867-1 · Cited by 255
Risk stratification for invasive aspergillosis in immunocompromised patients
Herbrecht, R., Bories, P., Moulin, J., Ledoux, M., & Letscher‐Bru, V. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06829.x · Cited by 148
Galactomannan and 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Aspergillosis
Lamoth, F. (2016) · Journal of Fungi · doi:10.3390/jof2030022 · Cited by 76
Invasive fungal infections in acute leukemia
Bhatt, V. R., Viola, G. M., & Ferrajoli, A. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711410098 · Cited by 71
Invasive Aspergillosis in Hematological Patients
Kimura, S.-I. (2016) · Medical Mycology Journal · doi:10.3314/mmj.57.j77 · Cited by 14
Metadata
- Authors
- Cordonnier, C., Pautas, C., Maury, S., Vekhoff, A., Farhat, H., Suarez, F., Dhédin, N., Isnard, F., Ades, L., Kuhnowski, F., Foulet, F., Kuentz, M., Maison, P., Bretagne, S., & Schwarzinger, M.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-04-15
- Volume
- 48
- Issue
- 8
- Pages
- 1042-1051
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2152583091
- Cited by
- 389
- References
- 28
- FWCI
- 26.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.